BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia

World News: . []

CAMBRIDGE Mass and BEIJING China Oct 12 2018 GLOBE NEWSWIRE) -- BeiGene Ltd NASDAQ BGNE HKEX 06160 a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-onc ology d...

More news and information about BeiGene, LTD.

Published By:

Globe Newswire: 11:00 GMT Friday 12th October 2018

Published: .

Search for other references to "beigene" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us